BIOPHARMA
ByIs Strategic Out-Licensing the Fastest Path to Global Scale? Restari Secures $230 Million PDE-5 Deal with AriBio
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Is AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a Paradigm Shift in Pharma R&D
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion Across Oncology and Obesity
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
